Liver enzymes in children with beta-Thalassemia major: Correlation with iron overload and viral hepatitis

Open Access Macedonian Journal of Medical Sciences

Volumn 3, Issue 2, 2015, Pages 287-292

  Salama, Khaled M ^a   Ibrahim, Ola M ^b   Kaddah, Ahmed M ^a   Boseila, Samia ^b   Ismail, Leila Abu ^b   Abdel Hamid, May M ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Beta thalassemia; Egyptian children; Iron overload; Liver enzymes; Viral hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CALCIUM; CARNITINE; FERRITIN; FOLIC ACID; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; LIVER ENZYME; TRANSFERRIN; VITAMIN D;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BLOOD ANALYSIS; BLOOD TRANSFUSION; CHELATION THERAPY; CHEMICAL ANALYSIS; CHILD; CLINICAL ASSESSMENT; CLINICAL FEATURE; COLORIMETRY; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATOSPLENOMEGALY; HUMAN; IRON BINDING CAPACITY; IRON OVERLOAD; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; QUESTIONNAIRE; REAL TIME POLYMERASE CHAIN REACTION; SPLENECTOMY; VIRUS HEPATITIS;

EID: 84935921491     PISSN: None     EISSN: 18579655     Source Type: Journal    
DOI: 10.3889/oamjms.2015.059     Document Type: Article

References (37)

1. Luz A, Sans M, Kimura E, Albuquerque D, et al. α-Thalassemia, HbS, and β-globin gene cluster haplotypes in two Afro-Uruguayan sub-populations from northern and southern Uruguay. Genet Mol Biol. 2006; 29: 595-600.
2. Karimi M, Ghavanini AA, and Kadiva MR. Regional mapping of the Gene frequency of β-Thalassemia in Fars Province, Iran during 1997-1998. Iran J Med Sci. 2000; 25(34):134-137.
3. Ameli M, Besharati S, Nemati K, Zamani F. Relationship between elevated liver enzyme with iron overload and viral hepatitis in thalassemia major patients in Northern Iran. Saudi Med J. 2008; 29(11):1611-5.
4. Ardalan FA, Osquei MR, Toosi MN, Irvanloo G. Synergic effect of chronic hepatitis C infection and beta thalassemia major with marked hepatic iron overload on liver fibrosis: a retrospective cross-sectional study. BMC Gastroenterol. 2004;4:17.
5. Papanikolaou G, Tzilianos M, Christakis JI, Bogdanos D et al., Hepcidin in iron overload disorders. Blood. 2005; 105: 4103-4105.
6. Feld J, Lee JY, Locarnini S. New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. Hepatology. 2003;38(3):545-53.
7. Khalifa AS, El-Sayed MH, Moustafa AO, Mohammed MM, Rady MS, Salama II. Hepatitis C virus infection in children with hematological diseases: risk factors and reliability of diagnosis assays. Egypt J Pediatr. 2002;19: 293-308.
8. Omar N, Salama K, Adolf S, El-Saeed GS, et al. Major risk of blood transfusion in hemolytic anemia patients. Blood Coagul Fibrinolysis. 2011; 22(4): 280-4.
9. El-Faramawy A, El-Rashidy O, Tawfik P, Hussein G. Transfusion Transmitted Hepatitis: Where Do We Stand Now? A One Center Study in Upper Egypt. Hepat Mon. 2012;12(4): 286-291.
10. Li CK, Chik K, Lam C, To K et al., Liver disease in transfusion dependent thalassemia major. Arch Dis Child. 2002; 86:344-7.
11. Cunningham M, Macklin E, Neufeld E, Cohen AR. Thalassemia Clinical Research Network. Complications of β-thalassemia major in North America. Blood. 2004; 104:34-39.
12. Angelucci E, Muretto P, Nicolucci A, Baronciani D et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 2002; 100:17-21.
13. Di Marco V, Capra M, Gagliardotto F, Borsellino Z et al. Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. Haematologica. 2008; 93(8):1243-1246.
14. Dimitrios K, Nikolaos J. Tsagarakis Evangelia F, Efthimios D, et al. Liver disease in adult transfusion -dependent beta-thalassaemic patients: investigating the role of iron overload and chronic HCV infection. Liver International. 2013; 33(3): 420-427.
15. Edoardo G, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005; 172(3): 367-379.
16. Ng RH, Brown BA, Valdes R Jr. Three commercial methods for serum ferritin compared and the high-dose "hook effect" eliminated. Clin Chem. 1983;29(6):1109-13.
17. Burtis CA, Ashford E. Editors, Tietz Textbook of Clinical Chemistry, 2nd ed., Saunders, 1994: 2195.
18. International federation of clinical chemistry. J Clin Chem Clin Bio. 1980; 18:5231.
19. Bergmeyer HU. Principles of enzymatic analysis. Verlag chemie (Bergmeyer, H. U., ed.), 1978: 35-40.
20. Szasz G. New substrates for measuring gamma-glutamyl transpeptidase activity. Z Klin Chem Klin Biochem. 1974;12(5):228.
21. Hurie M, Mast E, Davis J. Horizontal transmission of hepatitis B virus infection to U.S. born children of Hmong refugees. Pediatrics. 1992; 89: 269-273.
22. Choo QL, Weiner AJ, Overby L, Kuo G et al. Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. Br Med Bull. 1990;46:423-441.
23. Al-Salem AH, Nasserulla Z. Splenectomy for children with thalassemia. Int Surg. 2002; 87: 269-73.
24. Morsy M, Alnajar A, Almuzainy I, Alhawsawi Z et al. Splenectomized versus non-splenectomized thalassemia patients with thalassemia major. Echocardiographic comparison. Saudi Med J. 2008; 29: 1310-1314.
25. Taher A, Sheikh-Taha M, Koussa S, Inati I, et al. Comparison between desferrioxamine and deferiprone (L1) in iron-loaded thalassaemia patients. European Journal of Haematology. 2001; 67: 30-34.
26. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006; 107: 3738-3744.
27. Galanello R and Campus S. Defriprone chelation therapy for thalassemia major. Acta Haematol. 2009; 122:155-164.
28. El-Alfy MS, Sari TT, Lee CL, Tricta F, El-Beshlawy A. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. J Pediatr Hematol Oncol. 2010;32(8):601-5.
29. El-Beshlawy A, Mokhtar G, Abd El Ghafar E, Abd El Dayem MS et al. Assessment of Puberty in Relation to L-carnitine and Hormonal Replacement Therapy in β-thalassemic Patients. J Trop Pediatr. 2008; 54: 375-381.
30. Megahed S, Tayel S, Abdelrahim M, Ali A et al. Role of L-Carnitine in Treatment of β-Thalassemia Major Disease. Journal of Pediatric Sciences. 2011; 3(3):91.
31. Ruhl CE, Everhart JE. Relation of elevated serum alanine aminotransferase activity with iron and antioxidant levels in the United States. Gastroenterology. 2003; 124: 1821-1829.
32. El Gawhary S, Omar N, Abdel Rahman L, Mahmoud M. Hepatic viruses screening in multitransfused Egyptian thalassemia patients. J Arab Child. 2009;20(3):193-202.
33. Din G, Malik S, Ali I, Ahmed S, and Dasti JI. Prevalence of hepatitis C virus infection among thalassemia patients: A perspective from a multi-ethnic population of Pakistan. Asian Pac J Trop Med. 2014;71:127-133.
34. Mansour AK, Aly RM, Abdelrazek SY, Elghannam DM, Abdelaziz SM, Shahine DA, Darwish AM, Elmenshawy NM. Prevalence of HBV and HCV infection among multi-transfused Egyptian thalassemic patients. Hematol Oncol Stem Cell Ther. 2012;5(1):54-9.
35. Hussein E. Evaluation of infectious disease markers in multitransfused Egyptian children with thalassemia. Ann Clin Lab Sci. 2014;44(1):62-6.
36. El-Shanshory MR, Kabbash IA, Soliman HH, Nagy HM, Abdou SH. Prevalence of hepatitis C infection among children with β-thalassaemia major in Mid Delta, Egypt: a single centre study. Trans R Soc Trop Med Hyg. 2013;107(4):224-8.
37. Ocak S, Kaya H, Cetin M, Gali E et al. Seroprevalence of hepatitis B and hepatitis C in patients with thalassemia and sickle cell anemia in a long-term follow-up. Arch Med Res. 2006;37(7):895-8.